Quality initiatives: Guidelines for use of medical imaging during pregnancy and lactation

Radiographics

Volumn 32, Issue 3, 2012, Pages 897-911

  Trop, Isabelle ^a   Tremblay, Emilie ^a   Thérasse, Eric ^a   Thomassin Naggara, Isabelle ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LACTATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREGNANCY; PRENATAL EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; STANDARD; UNITED STATES;

FEMALE; HUMANS; LACTATION; MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RADIATION INJURIES; RADIATION PROTECTION; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84861130388     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.323115120     Document Type: Article

References (61)

1. Lazarus E, Debenedectis C, North D, Spencer PK, Mayo-Smith WW. Utilization of imaging in pregnant patients: 10-year review of 5270 examinations in 3285 patients-1997-2006. Radiology 2009;251(2): 517-524.
2. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol 2008;112(2 pt 1):333-340.
3. Brent RL. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am J Obstet Gynecol 2009;200 (1):4-24.
4. Ramapalan S, Bona N, Chandra K, Koren G. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. AJR Am J Roentgenol 2004;182(5):1107-1109.
5. ACOG Committee on Obstetric Practice. ACOG Committee Opinion, no. 299, September 2004 (replaces no. 158, September 1995): guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004;104(3):647-651.
6. Wall BF, Meara JR, Muirhead CR, Bury RF, Murray M. Protection of pregnant patients during diagnostic medical exposures to ionising radiation: advice from the Health Protection Agency, the Royal College of Radiologists and the College of Radiographers. Documents of the Health Protection Agency: Radiation, Chemical and Environmental Hazards. United Kingdom, 2009.
7. Brent RL. What are the reproductive and developmental risks of ionizing radiation? In: Hales B, Scialli A, Tassinari M, eds. Teratology primer. 2nd ed. Philadelphia, Pa: Thomas Jefferson University, 2010; 56-58.
8. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37:2-4.
9. Wrixon AD. New ICRP recommendations. J Radiol Prot 2008;28(2):161-168.
10. McCollough CH, Schueler BA, Atwell TD, et al. Radiation exposure and pregnancy: when should we be concerned? RadioGraphics 2007;27(4):909-917; discussion 917-918.
11. Pahade JK, Litmanovich D, Pedrosa I, Romero J, Bankier AA, Boiselle PM. Imaging pregnant patients with suspected pulmonary embolism: what the radiologist needs to know. RadioGraphics 2009;29(3): 639-654.
12. Wieseler KM, Bhargava P, Kanal KM,Vaidya S, Stewart BK, Dighe MK. Imaging in pregnant patients: examination appropriateness. RadioGraphics 2010;30(5):1215-1229; discussion 1230-1233.
13. Adair ER, Black DR. Thermoregulatory responses to RF energy absorption. Bioelectromagnetics 2003; 24(suppl 6):S17-S38.
14. De Wilde JP, Rivers AW, Price DL. A review of the current use of magnetic resonance imaging in pregnancy and safety implications for the fetus. Prog Biophys Mol Biol 2005;87(2-3):335-353.
15. Kanal E. Pregnancy and the safety of magnetic resonance imaging. Magn Reson Imaging Clin N Am 1994;2(2):309-317.
16. Kanal E, Barkovich AJ, Bell C, et al; ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007;188(6): 1447-1474.
17. Kok RD, de Vries MM, Heerschap A, van den Berg PP. Absence of harmful effects of magnetic resonance exposure at 1.5 T in utero during the third trimester of pregnancy: a follow-up study. Magn Reson Imaging 2004;22(6):851-854.
18. Baker PN, Johnson IR, Harvey PR, Gowland PA, Mansfield P. A three-year follow-up of children imaged in utero with echo-planar magnetic resonance. Am J Obstet Gynecol 1994;170(1 pt 1):32-33.
19. Myers C, Duncan KR, Gowland PA, Johnson IR, Baker PN. Failure to detect intrauterine growth restriction following in utero exposure to MRI. Br J Radiol 1998;71(845):549-551.
20. Hand JW, LiY, Hajnal JV. Numerical study of RF exposure and the resulting temperature rise in the foetus during a magnetic resonance procedure. Phys Med Biol 2010;55 (4):913-930.
21. Glover P, Hykin J, Gowland P, Wright J, Johnson I, Mansfield P. An assessment of the intrauterine sound intensity level during obstetric echo-planar magnetic resonance imaging. Br J Radiol 1995;68 (814):1090-1094.
22. American Academy of Pediatrics. Committee on Environmental Health. Noise: a hazard for the fetus and newborn. Pediatrics 1997;100(4):724-727.
23. Brasseur-Daudruy M, Ickowicz V, Eurin D. Fetal MRI: indications, limits and dangers [in French]. Gynecol Obstet Fertil 2007;35(7-8):678-683.
24. Medical Devices Agency. Guidelines for magnetic resonance diagnostic equipment in clinical use. London, England: Medicines and Healthcare products Regulatory Agency, 2002.
25. Webb JA, Thomsen HS, Morcos SK; Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol 2005;15(6): 1234-1240.
26. Carlson BM. Human embryology and developmental biology. 4th ed. St Louis, Mo: Mosby, 2008.
27. Kubik-Huch RA, Gottstein-Aalame NM Frenzel T, et al, Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology 2000; 216(2):555-558.
28. Garcia-Bournissen F, Shrim A, Koren G. Safety of gadolinium during pregnancy. Can Fam Physician 2006;52:309-310.
29. Bourjeily G, Chalhoub M, Phornphutkul C, Alleyne TC, Woodfield CA, Chen KK. Neonatal thyroid function: effect of a single exposure to iodinated contrast medium in utero. Radiology 2010;256(3): 744-750.
30. Atwell TD, Lteif AN, Brown DL, McCann M, Townsend JE, Leroy AJ. Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients. AJR Am J Roentgenol 2008; 191(1):268-271.
31. Smith VC, Svoren BM, Wolfsdorf JI. Hypothyroidism in a breast-fed preterm infant resulting from maternal topical iodine exposure. J Pediatr 2006; 149(4):566-567.
32. Stubbe P, Heidemann P, Schürnbrand P, Ulbrich R. Transient congenital hypothyroidism after amniofetography. Eur J Pediatr 1980;135(1):97-99.
33. Webb JAW. Pregnancy and lactation. In: Thomsen HS, Webb JAW, eds. Contrast media: safety issues and ESUR guidelines. 2nd ed. Berlin, Germany: Springer-Verlag, 2009; 95-101.
34. Robuschi G, Montermini M, Alboni A, et al. Cord blood iodothyronine and thyrotropin concentrations in newborns of mothers exposed to povidone iodine in the last trimester. J Endocrinol Invest 1987;10 (2):183-186.
35. Casteels K, Punt S, Bramswig J. Transient neonatal hypothyroidism during breastfeeding after post-na-tal maternal topical iodine treatment. Eur J Pediatr 2000;159(9):716-717.
36. American College of Radiology. ACR committee on drugs and contrast media. ACR Manual on Contrast Media. 7th ed. Reston,Va: American College of Radiology, 2010.
37. U.S. Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucm142882.htm. Accessed April 19, 2011.
38. Colletti PM, Sylvestre PB. Magnetic resonance imaging in pregnancy. Magn Reson Imaging Clin N Am 1994;2(2):291-307.
39. ProHance (gadoteridol). Bracco Diagnostics. Product information available at http://www.prohance.com/PDFs/ProHance.pdf. Accessed April 19, 2011.
40. Magnevist Product Monograph. Bayer Inc, Toronto, Ontario. http://www.bayer.ca/files/MAGNEVIST-PM-ENG-23OCT2009-128279.pdf. Revised October 23, 2009. Accessed March 29, 2011.
41. Omniscan Product Monograph. GE Healthcare Canada Inc, Mississauga, Ontario. http://www.gehealthcare.com/caen/md/docs/omniscaneng.pdf. Revised October 17, 2007. Accessed March 29, 2011.
42. De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand 2007;86(1):99-101.
43. Marcos HB, Semelka RC,Worawattanakul S. Normal placenta: gadolinium-enhanced dynamic MR imaging. Radiology 1997;205(2):493-496.
44. Tanaka YO, Sohda S, Shigemitsu S, Niitsu M, Itai Y. High temporal resolution dynamic contrast MRI in a high risk group for placenta accreta. Magn Reson Imaging 2001;19(5):635-642.
45. Mühler MR, Clement O, Salomon LJ, et al. Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology 2011;258(2): 455-460.
46. Normann PT, Joffe P, Martinsen I, Thomsen HS. Quantification of gadodiamide as Gd in serum, peritoneal dialysate and faeces by inductively coupled plasma atomic emission spectroscopy and comparative analysis by high-performance liquid chromatography. J Pharm Biomed Anal 2000;22(6):939-947.
47. Gadovist 1.0 Product Monograph. Bayer Inc,Toronto, Ontario. http://www.bayer.ca/files/GADO-VIST-PM-ENG-13OCT2010-131080.pdf?#. Revised October 13, 2010. Accessed March 29, 2011.
48. MultiHance Product Monograph. Bracco. http://multihanceusa.com/downloads/04MUL0050B%20v8.pdf. 2005. Accessed March 29, 2011.
49. World Health Organization. Breast-feeding recommendations. http://www.who.int/mediacentre/news/statements/2011/breastfeeding_20110115/en/. Accessed April 19, 2011.
50. Leung AK, Sauve RS. Breast is best for babies. J Natl Med Assoc 2005;97(7):1010-1019.
51. Newman J. Breastfeeding and radiologic procedures. Can Fam Physician 2007;53(4):630-631.
52. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343(2):118-126.
53. Rofsky NM, Weinreb JC, Litt AW. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging 1993;3(1): 131-132.
54. Schmiedl U, Maravilla KR, Gerlach R, Dowling CA. Excretion of gadopentetate dimeglumine in human breast milk. AJR Am J Roentgenol 1990;154(6): 1305-1306.
55. Nielsen ST, Matheson I, Rasmussen JN, Skinnemoen K, Andrew E, Hafsahl G. Excretion of iohexol and metrizoate in human breast milk. Acta Radiol 1987;28(5):523-526.
56. Bettmann MA. Frequently asked questions: iodinated contrast agents. RadioGraphics 2004;24(spec issue):S3-S10.
57. Omnipaque Product Monograph. GE Healthcare Canada Inc, Mississauga, Ontario. http://www.gehealthcare.com/caen/md/docs/omnipaquepieng.pdf. Published November 8, 2006. Accessed March 29, 2011.
58. Visipaque Product Monograph. GE Healthcare Canada Inc, Mississauga, Ontario. http://www.gehealthcare.com/caen/md/docs/visipaquepieng.pdf. Published May 25, 2006. Accessed March 29, 2011.
59. Patel SJ, Reede DL, Katz DS, Subramaniam R, Amorosa JK. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. RadioGraphics 2007;27(6): 1705-1722.
60. Hylton NM. Suspension of breast-feeding following gadopentetate dimeglumine administration. Radioogy 2000;216(2):325-326.
61. Berlin L. Radiation exposure and the pregnant patient. AJR Am J Roentgenol 1996;167(6): 1377-1379.